Format

Send to

Choose Destination
Best Pract Res Clin Haematol. 2017 Sep;30(3):175-183. doi: 10.1016/j.beha.2017.07.008. Epub 2017 Aug 3.

How should we treat the AYA patient with newly diagnosed ALL?

Author information

1
Adolescent & Young Adult Hematology Unit, Saint-Louis Hospital, EA-3518, Paris 7 University, 1 avenue Claude Vellefaux, 75010, Paris, France. Electronic address: nicolas.boissel@aphp.fr.

Abstract

Adolescent and young adult (AYA) patients with acute lymphoblastic leukaemia (ALL) are recognized as a unique population with specific characteristics and needs. In adolescents aged 15-20 years old, the use of full paediatric protocols is supported by many comparative studies of paediatric and adult cooperative groups. In young adults, growing evidence suggests that paediatric-inspired approaches may also improve outcomes and lead to long-term survival rates of almost 70%. In the last decade, better knowledge of ALL oncogenic landscape, age distribution, and minimal residual disease prognostic impact have improved risk stratification. New targets have emerged mostly in the heterogeneous subgroup of Philadelphia-like ALL and will require both in-depth molecular investigations and specific evaluations in rare subgroups of ALL. The remaining gap with the excellent results reported in children has many other contributing factors that should not be underestimated including late or difficult access to care, or poor adherence to treatment.

KEYWORDS:

Acute lymphoblastic leukemia; Adolescent and young adult; Therapy

PMID:
29050690
DOI:
10.1016/j.beha.2017.07.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center